

Saviana Gandolfo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2110533/publications.pdf>

Version: 2024-02-01

27
papers

512
citations

933264

10
h-index

677027

22
g-index

28
all docs

28
docs citations

28
times ranked

696
citing authors

#	ARTICLE	IF	CITATIONS
1	International consensus: What else can we do to improve diagnosis and therapeutic strategies in patients affected by autoimmune rheumatic diseases (rheumatoid arthritis, spondyloarthritides,) TJ ETQq1 1 0.784314 rgBT /Overlock 107	2.5	107
2	Medical data quality assessment: On the development of an automated framework for medical data curation. <i>Computers in Biology and Medicine</i> , 2019, 107, 270-283.	3.9	67
3	Efficacy and safety of belimumab given for 12 months in primary Sjögren's syndrome: the BELISS open-label phase II study. <i>Rheumatology</i> , 2015, 54, kev257.	0.9	66
4	Primary Sjögren's Syndrome of Early and Late Onset: Distinct Clinical Phenotypes and Lymphoma Development. <i>Frontiers in Immunology</i> , 2020, 11, 594096.	2.2	45
5	Cryoglobulinemia in Sjögren Syndrome: A Disease Subset that Links Higher Systemic Disease Activity, Autoimmunity, and Local B Cell Proliferation in Mucosa-associated Lymphoid Tissue. <i>Journal of Rheumatology</i> , 2017, 44, 1179-1183.	1.0	33
6	Predicting lymphoma development in patients with Sjögren's syndrome. <i>Expert Review of Clinical Immunology</i> , 2019, 15, 929-938.	1.3	31
7	Sjögren's Syndrome: The Clinical Spectrum of Male Patients. <i>Journal of Clinical Medicine</i> , 2020, 9, 2620.	1.0	26
8	A biomarker for lymphoma development in Sjogren's syndrome: Salivary gland focus score. <i>Journal of Autoimmunity</i> , 2021, 121, 102648.	3.0	24
9	TREX1 variants in Sjogren's syndrome related lymphomagenesis. <i>Cytokine</i> , 2020, 132, 154781.	1.4	18
10	Efficacy of belimumab and targeting of rheumatoid factor-positive B-cell expansion in Sjögren's syndrome: follow-up after the end of the phase II open-label BELISS study. <i>Clinical and Experimental Rheumatology</i> , 2016, 34, 311-4.	0.4	15
11	Peripheral Nervous System Involvement in Sjögren's Syndrome: Analysis of a Cohort From the Italian Research Group on Sjögren's Syndrome. <i>Frontiers in Immunology</i> , 2021, 12, 615656.	2.2	12
12	Emerging drugs for primary Sjögren's syndrome. <i>Expert Opinion on Emerging Drugs</i> , 2019, 24, 121-132.	1.0	10
13	Ultrasound and Bioptic Investigation of Patients with Primary Sjögren's Syndrome. <i>Journal of Clinical Medicine</i> , 2021, 10, 1171.	1.0	10
14	Overcoming the Barriers That Obscure the Interlinking and Analysis of Clinical Data Through Harmonization and Incremental Learning. <i>IEEE Open Journal of Engineering in Medicine and Biology</i> , 2020, 1, 83-90.	1.7	9
15	Double anti-B cell and anti-BAFF targeting for the treatment of primary Sjögren's syndrome. <i>Clinical and Experimental Rheumatology</i> , 2019, 37 Suppl 118, 199-208.	0.4	9
16	Addressing the clinical unmet needs in primary Sjögren's Syndrome through the sharing, harmonization and federated analysis of 21 European cohorts. <i>Computational and Structural Biotechnology Journal</i> , 2022, 20, 471-484.	1.9	7
17	The evaluation of disease activity in Sjögren's syndrome based on the degree of MALT involvement: glandular swelling and cryoglobulinaemia compared to ESSDAI in a cohort study. <i>Clinical and Experimental Rheumatology</i> , 2018, 36 Suppl 112, 150-156.	0.4	7
18	Articular and Peripheral Nervous System Involvement Are Linked to the Long-Term Outcome in Primary Sjögren's Syndrome: The Relevance of Single Organ Manifestations Rather Than a Composite Score as Predictors. <i>Frontiers in Immunology</i> , 2019, 10, 1527.	2.2	5

#	ARTICLE	IF	CITATIONS
19	Shared Pathogenetic Features Between Common Variable Immunodeficiency and Sjögren's Syndrome: Clues for a Personalized Medicine. <i>Frontiers in Immunology</i> , 2021, 12, 703780.	2.2	3
20	Type I interferon signature may influence the effect of belimumab on immunoglobulin levels, including rheumatoid factor in Sjögren's syndrome. <i>Clinical and Experimental Rheumatology</i> , 2017, 35, 719-720.	0.4	3
21	Enhancing medical data quality through data curation: a case study in primary Sjögren's syndrome. <i>Clinical and Experimental Rheumatology</i> , 2019, 37 Suppl 118, 90-96.	0.4	2
22	Thymic stromal lymphopoietin expression from benign lymphoproliferation to malignant B-cell lymphoma in primary Sjögren's syndrome. <i>Clinical and Experimental Rheumatology</i> , 2019, 37 Suppl 118, 55-64.	0.4	2
23	Sjögren's Syndrome. , 2018, , 323-335.		0
24	AB0166...ENHANCING THE QUALITY OF CLINICAL DATA THROUGH DATA CURATION IN PRIMARY SJÖGREN'S SYNDROME. , 2019, , .		0
25	SAT0190...LYMPHOMA IN PRIMARY SJÖGREN'S SYNDROME: A RETROSPECTIVE CLINICAL STUDY WITH PATIENTS FROM THE UPA (UDINE, PISA, ATHENS) GROUP. , 2019, , .		0
26	Validation of thymic stromal lymphopoietin as a biomarker of primary Sjögren's syndrome and related lymphoproliferation: results in independent cohorts. <i>Clinical and Experimental Rheumatology</i> , 2020, 38 Suppl 126, 189-194.	0.4	0
27	A federated AI strategy for the classification of patients with Mucosa Associated Lymphoma Tissue (MALT) lymphoma across multiple harmonized cohorts. , 2021, 2021, 1666-1669.		0